Insider · CIK 0001889532
Barry Fishman
Files at MDCX (Medicus Pharma Ltd.). First filing -, latest -.
In brief
Barry Fishman files SEC Form 4 as director at MDCX (Medicus Pharma Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Barry Fishman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | MDCX Medicus Pharma Ltd. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Mar 30, 2026 | MDCX Medicus Pharma Ltd. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Dec 16, 2025 | MDCX Medicus Pharma Ltd. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Jul 22, 2025 | MDCX Medicus Pharma Ltd. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jul 24, 2025 |
Questions about Barry Fishman
Answered from the filings on this page, as of the latest one.
Is Barry Fishman buying or selling?
Barry Fishman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Barry Fishman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Barry Fishman has 0.
Where does Barry Fishman file Form 4?
Barry Fishman has filed Form 4 at MDCX (Medicus Pharma Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.